Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of BI 764198 Formulations in Healthy Subjects
NCT06955754Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apecotrep in focal segmental glomerulosclerosis (FSGS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point up to 4 days and Maximum measured concentration up to 4 days. Started May 2025; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT06955754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955754.